Early Use of Rosuvastatin in Acute Coronary Syndromes: Targeting Platelet-Leukocyte Interactions
Status:
Completed
Trial end date:
2014-02-01
Target enrollment:
Participant gender:
Summary
The central hypothesis for this work is that platelet - leukocyte interactions play a
critical role in the pathogenesis of acute ischemic events. The primary objective of the
study is to determine if early, high-dose administration of the HMG-CoA reductase inhibitor
rosuvastatin in the setting of acute coronary syndrome and percutaneous coronary intervention
exerts beneficial vascular effects by reducing platelet - leukocyte interactions.